FDA grants orphan status for targeted drug tenagisib (RP6530) for skin T-cell lymphoma

recently, RhizenPharmaceutical son
hasing(
FDA
has granted the targeted drug tenagisib (RP6530) the status of an orphan drug for the treatment of skin T-cell lymphoma (CTCL)Prior to, the FDA also granted the drug the status of orphan sedatives and fast-track status for the treatment of peripheral T-cell lymphoma (PTCL)about tenagisib
tenagisib is a highly selective, orally active inositol phosphate 3-kinase and kinase pyridine (PI3K-nixen/niobium) bi-effect inhibitorPI3K and PI3K are two kinases that play a key role in the growth and survival of malignant B-cells and T-cells, and their signaling pathways can cause the proliferation of malignant B-cells and T-cells, and may also play a role in the formation and maintenance of tumor microenvironmentsin the study of whole blood, cell and enzyme activity, tenagisib can effectively inhibit PI3K-ni/sin, in addition to inhibiting the growth of perantomic cancer cell lines and leukemia/lymphoma cells, tenagisib also plays an important role in the regulation of tumor microenvironmentpreclinical studieshave shown that tenagisib can reprogram macrophages from an immunosuppressive M2 phenotype (pro-tumor, precancerous) to an inflammatory M1 phenotype (anti-tumor), which will hopefully increase the activity of immunocheckpoint inhibitors or customer resistance to such drugsjust recently, the FDA granted priority review seeking approval from Verastem's(oral dual-effect PI3K-s/duvelisib for the treatment of 3 types of hematologic malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and flotoma (FL) Rhizen
Rhizen is a clinical-stage biopharmaceutical company based in Rasaud, Switzerland, focused on the discovery and development of innovative small molecule drugs targeting signaling networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases, and metabolic diseases since its inception in 2008, Rchizen has created a variety of research and development pipelines that include a wide range of
new drug that target synths and immune-related cellular signaling pathways